卖什么
Helping Plastic Surgeons Rebuild Fat
商业模式拆解
买家：谁掌握预算？
未核实Plastic and reconstructive surgeons and hospitals/surgery centers buying a surgical biomaterial (inferred).
触发点：什么让他们现在购买？
Synthetic implants and fillers have side effects; existing biomaterials are costly allografts or short-lived synthetic placeholders; need to improve fat-grafting volume retention in breast and facial reconstruction.
工作流：什么输入变成什么输出？
Harvest fat by liposuction, mix with Fractomer matrix, inject as one slurry, matrix solidifies at body temperature into a porous scaffold that stabilizes and vascularizes the graft.
经济账：省了什么，怎么收费？
未核实Medical device/biomaterial sold per procedure (inferred); pre-commercial, no financials stated.
渠道：怎么接触到客户？
未核实Pre-commercial; accepted to MedTech Innovator 2025; would sell to surgeons via regulatory clearance (inferred).
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2020 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.